{"id":246232,"date":"2026-09-15T11:11:45","date_gmt":"2026-09-15T05:41:45","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=246232"},"modified":"2026-09-15T11:11:45","modified_gmt":"2026-09-15T05:41:45","slug":"dr-reddys-laboratories-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Dr Reddys Laboratories Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dr. Reddy&#8217;s Laboratories share price Rs 1,164.90 on 15 September 2026, down 0.05%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 436.00 crore. Q2 FY26 base a profit of Rs 1,337.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Dr Reddys Laboratories Q2 results date for FY27 is not confirmed, and Dr. Reddy&#8217;s Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 8,828.00 crore in revenue and a profit of Rs 1,337.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Dr Reddys Laboratories Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr. Reddy&#8217;s Laboratories Ltd.<\/a>, a Hyderabad-headquartered pharmaceutical company producing generic drugs, active pharmaceutical ingredients and biosimilars for markets across India, the US, Russia and Europe. The stock traded at Rs 1,164.90 on the NSE on 15 September 2026, down 0.05% from the previous close of Rs 1,165.50, about 17.7% below its 52-week high of Rs 1,414.90 and 5.8% above its 52-week low of Rs 1,101.00.<\/p>\n<p>What makes the Dr Reddys Laboratories Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 8,828.00 crore of revenue and a profit of Rs 1,337.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 8,100.00 crore and a profit of Rs 436.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=drreddy_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#When_Is_the_Dr_Reddys_Laboratories_Q2_Results_FY27_Date\" title=\"When Is the Dr Reddys Laboratories Q2 Results FY27 Date?\">When Is the Dr Reddys Laboratories Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Dr_Reddys_Laboratories_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Dr Reddys Laboratories Q2 Results Expectations: What the Market Is Actually Tracking\">Dr Reddys Laboratories Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Dr_Reddys_Laboratories_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Dr Reddys Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Dr Reddys Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Dr_Reddys_Laboratories_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Dr Reddys Laboratories Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Dr Reddys Laboratories Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Dr_Reddys_Laboratories_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Dr. Reddy&#8217;s Laboratories Quarterly Results Trend Over the Last Four Quarters\">Dr. Reddy&#8217;s Laboratories Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Dr_Reddys_Laboratories_Q2_Results_FY27\" title=\"Key Factors That Could Shape Dr Reddys Laboratories Q2 Results FY27\">Key Factors That Could Shape Dr Reddys Laboratories Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Depressed_Base_From_Mar26_Shapes_Comparisons\" title=\"Depressed Base From Mar26 Shapes Comparisons\">Depressed Base From Mar26 Shapes Comparisons<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Valuation_Against_a_Choppy_Earnings_Trend\" title=\"Valuation Against a Choppy Earnings Trend\">Valuation Against a Choppy Earnings Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Stock_Trading_Below_Both_Key_Averages\" title=\"Stock Trading Below Both Key Averages\">Stock Trading Below Both Key Averages<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Dr_Reddys_Laboratories_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Dr Reddys Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print\">Dr Reddys Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Dr_Reddys_Laboratories_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Dr Reddys Laboratories Q2 Results Are Announced\">What Investors Should Watch When Dr Reddys Laboratories Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Dr_Reddys_Laboratories_Q2_Results_FY27\" title=\"Conclusion on Dr Reddys Laboratories Q2 Results FY27\">Conclusion on Dr Reddys Laboratories Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#FAQs_on_Dr_Reddys_Laboratories_Q2_Results_FY27\" title=\"FAQs on Dr Reddys Laboratories Q2 Results FY27\">FAQs on Dr Reddys Laboratories Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_is_the_Dr_Reddys_Laboratories_Q2_results_date_for_FY27\" title=\"What is the Dr Reddys Laboratories Q2 results date for FY27?\">What is the Dr Reddys Laboratories Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Dr_Reddys_Laboratories_Q2_results_2026_cover\" title=\"What quarter do the Dr Reddys Laboratories Q2 results 2026 cover?\">What quarter do the Dr Reddys Laboratories Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_were_the_Dr_Reddys_Laboratories_Q1_FY27_results\" title=\"What were the Dr. Reddy&#8217;s Laboratories Q1 FY27 results?\">What were the Dr. Reddy&#8217;s Laboratories Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_were_Dr_Reddys_Laboratories_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Dr. Reddy&#8217;s Laboratories Q2 FY26 results in the September 2025 quarter?\">What were Dr. Reddy&#8217;s Laboratories Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Dr_Reddys_Laboratories_Q2_results_expectations_this_quarter\" title=\"What are the main Dr Reddys Laboratories Q2 results expectations this quarter?\">What are the main Dr Reddys Laboratories Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#What_is_Dr_Reddys_Laboratories_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Dr. Reddy&#8217;s Laboratories share price today ahead of the Q2 earnings?\">What is Dr. Reddy&#8217;s Laboratories share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations\/#Is_Dr_Reddys_Laboratories_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Dr. Reddy&#8217;s Laboratories a good stock to buy before the Q2 results?\">Is Dr. Reddy&#8217;s Laboratories a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Dr_Reddys_Laboratories_Q2_Results_FY27_Date\"><\/span><strong>When Is the Dr Reddys Laboratories Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Dr Reddys Laboratories Q2 results date for FY27 is not confirmed. As of 15 September 2026, Dr. Reddy&#8217;s Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Dr Reddys Laboratories Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Dr Reddys Laboratories Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Dr. Reddy&#8217;s Laboratories.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Dr Reddys Laboratories Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Dr Reddys Laboratories Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Dr. Reddy&#8217;s Laboratories. The Dr Reddys Laboratories Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>Dr. Reddy&#8217;s Laboratories posted operating profit of Rs 2,174 crore in Jun25, Rs 2,010 crore in Sep25 and Rs 1,888 crore in Dec25, with operating margin steady in the 22-25% range across these three quarters. This run-rate is a useful baseline for readers assessing whether the business has stabilised heading into the September 2026 quarter.<\/p>\n<p>The Mar26 quarter marked a sharp break from this pattern: operating profit collapsed to just Rs 382 crore and operating margin fell to 5% from 22% in the prior quarter, while net profit dropped to Rs 221 crore from Rs 1,190 crore. The effective tax rate also turned negative (-11%) that quarter, a combination strongly suggestive of an unreported one-off charge or impairment rather than a routine operating slowdown, and this is an important factual anomaly for readers to be aware of.<\/p>\n<p>Jun26 showed only a partial recovery, with operating margin at 11% and net profit at Rs 436 crore, still well below the Rs 1,300-1,400 crore net profit run-rate seen in Jun25 through Dec25. Because Mar26 and Jun26 represent a depressed base relative to the earlier quarters, any year-over-year or quarter-over-quarter comparison built around the September 2026 quarter&#8217;s results should account for this low base rather than treating recent quarters as representative of normal operating levels.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Dr. Reddy&#8217;s Laboratories Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Dr Reddys Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Reddy&#8217;s Laboratories Ltd. reported revenue of Rs 8,100.00 crore in Q1 FY27, down 5.51% from Rs 8,572.00 crore in Q1 FY26, and a profit of Rs 436.00 crore at the net level, down 69.08% from Rs 1,410.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was up 7.34% over the March 2026 quarter figure of Rs 7,546.00 crore, and net profit was up 97.29% from Rs 221.00 crore in Q4 FY26. Operating margin stood at 11.0% in Q1 FY27 against 23.0% in the September 2025 quarter, which is the comparison the Dr Reddys Laboratories Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Dr_Reddys_Laboratories_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Dr Reddys Laboratories Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Reddy&#8217;s Laboratories Ltd. reported revenue of Rs 8,828.00 crore and a profit of Rs 1,337.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Dr Reddys Laboratories Q2 results preview.<\/p>\n<p>Net profit in that base quarter was above the Rs 436.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 8,828.00 crore sits above the Rs 8,100.00 crore of the June 2026 quarter, which frames how much sequential movement the Dr Reddys Laboratories Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Dr. Reddy&#8217;s Laboratories Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>8,828.00<\/td>\n<td>1,337.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>8,753.00<\/td>\n<td>1,190.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>7,546.00<\/td>\n<td>221.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>8,100.00<\/td>\n<td>436.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Dr Reddys Laboratories Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 7,546.00 crore to Rs 8,828.00 crore, and net profit from Rs 221.00 crore to Rs 1,337.00 crore. That spread is the honest context for the Dr Reddys Laboratories Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Dr_Reddys_Laboratories_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Dr Reddys Laboratories Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Dr Reddys Laboratories Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Dr. Reddy&#8217;s Laboratories has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Depressed_Base_From_Mar26_Shapes_Comparisons\"><\/span><strong>Depressed Base From Mar26 Shapes Comparisons<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit fell from Rs 1,888 crore in Dec25 to Rs 382 crore in Mar26 before only partially recovering to Rs 860 crore in Jun26, a pattern that keeps both quarters well below the roughly Rs 2,000 crore operating profit levels seen in Jun25 through Dec25. This gap is the key context for interpreting any comparison drawn against the September 2026 quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Against_a_Choppy_Earnings_Trend\"><\/span><strong>Valuation Against a Choppy Earnings Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr. Reddy&#8217;s trades at a trailing P\/E of about 30.2 and a price-to-book ratio of roughly 2.57, with return on equity at 11.2% and a debt-to-equity ratio of 0.20, at the current price of Rs 1,164.90. These figures are stated factually, without implying whether the multiple appropriately reflects the recent earnings volatility.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Stock_Trading_Below_Both_Key_Averages\"><\/span><strong>Stock Trading Below Both Key Averages<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock&#8217;s 52-week range spans Rs 1,101 to Rs 1,414.9, with the current price of Rs 1,164.90 below both its 50-day moving average of Rs 1,187.49 and its 200-day moving average of Rs 1,250.68. An RSI of 38.66 reflects a relatively subdued technical setup heading into results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Dr Reddys Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Reddy&#8217;s Laboratories share price today is Rs 1,164.90 on the NSE, down Rs 0.60 or 0.05% from the previous close of Rs 1,165.50 on 15 September 2026, ahead of the Dr Reddys Laboratories Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (15 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>DRREDDY<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 1,164.90<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 1,414.90<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 1,101.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 97,282 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>30.20<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>2.57<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 38.57<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 454.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.20<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>11.2%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 1187.49<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 1250.68<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>38.66<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades below both its 50-day average of Rs 1187.49 and its 200-day average of Rs 1250.68, with a 14-day RSI of 38.66. None of this is a view on where the shares go once the Dr Reddys Laboratories Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr. Reddy&#8217;s Laboratories Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Dr_Reddys_Laboratories_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Dr Reddys Laboratories Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Dr Reddys Laboratories Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 8,828.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 1,337.00 crore in that same quarter<\/li>\n<li>Operating margin against 11.0% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Dr Reddys Laboratories Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Dr_Reddys_Laboratories_Q2_Results_FY27\"><\/span><strong>Conclusion on Dr Reddys Laboratories Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Dr Reddys Laboratories Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Dr. Reddy&#8217;s Laboratories Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Dr Reddys Laboratories Q2 results FY27 print faces a base of Rs 8,828.00 crore in revenue and a profit of Rs 1,337.00 crore, with the most recent quarter having delivered Rs 8,100.00 crore and a profit of Rs 436.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Dr. Reddy&#8217;s Laboratories, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Dr_Reddys_Laboratories_Q2_Results_FY27\"><\/span><strong>FAQs on Dr Reddys Laboratories Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Dr_Reddys_Laboratories_Q2_results_date_for_FY27\"><\/span><strong>What is the Dr Reddys Laboratories Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Dr Reddys Laboratories Q2 results date for FY27 is not confirmed. Dr. Reddy&#8217;s Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Dr_Reddys_Laboratories_Q2_results_2026_cover\"><\/span><strong>What quarter do the Dr Reddys Laboratories Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Dr Reddys Laboratories Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Dr. Reddy&#8217;s Laboratories Ltd. reports revenue, operating profit and net profit for that period, and the Dr Reddys Laboratories Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Dr_Reddys_Laboratories_Q1_FY27_results\"><\/span><strong>What were the Dr. Reddy&#8217;s Laboratories Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Reddy&#8217;s Laboratories Ltd. reported revenue of Rs 8,100.00 crore in Q1 FY27 and a profit of Rs 436.00 crore at the net level. Revenue was down 5.51% versus Q1 FY26 and net profit was down 69.08% from Rs 1,410.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Dr_Reddys_Laboratories_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Dr. Reddy&#8217;s Laboratories Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Reddy&#8217;s Laboratories Ltd. reported revenue of Rs 8,828.00 crore and a profit of Rs 1,337.00 crore in Q2 FY26. Operating margin was 23.0%. Those figures form the base for the Dr Reddys Laboratories Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Dr_Reddys_Laboratories_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Dr Reddys Laboratories Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Dr Reddys Laboratories Q2 results expectations centre on revenue against the Rs 8,828.00 crore base, net profit against a profit of Rs 1,337.00 crore, operating margin against 11.0% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Dr_Reddys_Laboratories_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Dr. Reddy&#8217;s Laboratories share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Reddy&#8217;s Laboratories share price is Rs 1,164.90 on the NSE as of 15 September 2026, down 0.05% from Rs 1,165.50. The stock is about 17.7% below its 52-week high of Rs 1,414.90 and 5.8% above its 52-week low of Rs 1,101.00, at a market capitalisation of Rs 97,282 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Dr_Reddys_Laboratories_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Dr. Reddy&#8217;s Laboratories a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Dr. Reddy&#8217;s Laboratories Ltd. The stock trades at a price-to-book ratio of 2.57 with a return on equity of 11.2%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Dr Reddys Laboratories Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Dr Reddys Laboratories Q2 results date for FY27 is not confirmed. Dr. Reddy's Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Dr Reddys Laboratories Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Dr Reddys Laboratories Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Dr. Reddy's Laboratories Ltd. reports revenue, operating profit and net profit for that period, and the Dr Reddys Laboratories Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Dr. Reddy's Laboratories Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr. Reddy's Laboratories Ltd. reported revenue of Rs 8,100.00 crore in Q1 FY27 and a profit of Rs 436.00 crore at the net level. Revenue was down 5.51% versus Q1 FY26 and net profit was down 69.08% from Rs 1,410.00 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Dr. Reddy's Laboratories Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr. Reddy's Laboratories Ltd. reported revenue of Rs 8,828.00 crore and a profit of Rs 1,337.00 crore in Q2 FY26. Operating margin was 23.0%. Those figures form the base for the Dr Reddys Laboratories Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Dr Reddys Laboratories Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Dr Reddys Laboratories Q2 results expectations centre on revenue against the Rs 8,828.00 crore base, net profit against a profit of Rs 1,337.00 crore, operating margin against 11.0% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Dr. Reddy's Laboratories share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr. Reddy's Laboratories share price is Rs 1,164.90 on the NSE as of 15 September 2026, down 0.05% from Rs 1,165.50. The stock is about 17.7% below its 52-week high of Rs 1,414.90 and 5.8% above its 52-week low of Rs 1,101.00, at a market capitalisation of Rs 97,282 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Dr. Reddy's Laboratories a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Dr. Reddy's Laboratories Ltd. The stock trades at a price-to-book ratio of 2.57 with a return on equity of 11.2%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Reddys Laboratories Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Dr. Reddy&#8217;s Laboratories Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":246231,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-246232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["246231"],"rank_math_title":["Dr Reddy's Labs Q2 FY27: Results Preview"],"rank_math_description":["Dr Reddys Laboratories Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Dr Reddys Laboratories Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/dr-reddys-laboratories-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/246232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=246232"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/246232\/revisions"}],"predecessor-version":[{"id":246233,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/246232\/revisions\/246233"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/246231"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=246232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=246232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=246232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}